ClinicalTrials.gg
CompletedNCT03656926BOSTON-2Updated Feb 10, 2026Results posted

Efficacy + Safety of Liposome Cyclosporine A to Treat Bronchiolitis Obliterans Post Double Lung Transplant (BOSTON-2)

A Phase 3 interventional study of Liposomal Cyclosporine A and Standard of Care in Bronchiolitis Obliterans, Chronic Rejection of Lung Transplant and Lung Transplant Rejection, sponsored by Zambon SpA. Completed at 40 sites in 9 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-02-10.

Sponsored by Zambon SpA · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
169
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 34 studies in Bronchiolitis Obliterans with a site in United States — 5 open to participants now, 5 under way, none of them phase 3. Bronchiolitis Obliterans · United States.

Enrollment
2nd of 25
169 · median 19
Started
2019
with 2 others
Phase 3
5 of 34
none open now
Registered
22nd of 34
by date
Lead sponsor
3 of 34
Zambon SpA

Among the 34 studies in Bronchiolitis Obliterans with a site in United States, this one is the 2nd largest by enrollment of the 25 interventional ones that give a count, is one of 3 that started in 2019, is one of 5 in phase 3, and was the 22nd registered.

Bronchiolitis Obliterans

82 studies on the registry are indexed under Bronchiolitis Obliterans; 9 are open to participants now.

Browse Bronchiolitis Obliterans studies →

Open to participants now

5 of the 34 studies in Bronchiolitis Obliterans with a site in United States are open now. Recruiting first, the newest first:

All 5 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 9 Bronchiolitis Obliterans studies recruiting now, 5 set no upper age limit and 4 stop at 75 or younger; 7 take children under 18; 2 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 34 studies in Bronchiolitis Obliterans with a site in United States, or all of them as a file.
02

Study summary

The objective of this trial was to assess the efficacy and safety of aerosolized liposomal cyclosporine A (L-CsA) as add-on therapy to standard of care (SoC) as compared to SoC alone in double lung transplant (DLT) recipients with chronic lung allograft dysfunction (CLAD)-bronchiolitis obliterans syndrome (BOS).

Read the detailed description

This was a Phase III, open-label, prospective, multicenter, randomized, controlled clinical trial of L-CsA for the treatment of BOS in adults following DLT. The patient population was recipients of a double pulmonary allograft, > or = 18 years old, with clinically defined CLAD--BOS with screening FEV1 >or = 51% of personal best FEV1 value post-transplant during the Screening period.

The rationale for an open-label study was driven by concerns that a sucrose-containing placebo formulation could increase a potential risk of pulmonary infection without the benefit of L-CsA. Sucrose is a lyoprotectant in the manufacturing process. After carefully considering alternative options for lyoprotection, no sugar-free alternatives that would qualify as a real placebo (i.e., undistinguishable by means of appearance, taste, or smell) could be identified.

Therefore, an open-label, randomized controlled trial versus SoC was the only suitable alternative.

An open-label clinical trial generally bears the potential for bias in patient treatment and care, and thus trial outcome. However, for this trial the risk of bias is considered low because of the following reasons:

  • During the trial, the general treatment of BOS was use of immunosuppressive therapy to the highest tolerable level unless limited by systemic toxicity. As inhaled L-CsA has not been associated with additional systemic drug burden, dose reductions or adaptations of other components of the immunosuppressive cocktail would not be required and were not desired.
  • The selected primary endpoint FEV1 is an objective parameter and its measurement was performed according to recommended guidelines of American Thoracic Society (ATS)/European Respiratory Society (ERS) which had to be respected by each participating center. Following this methodology, a subjective and intentional manipulation of outcome was highly unlikely even if healthcare professional and patient were aware of the treatment allocation.
  • Pulmonary function technicians, respiratory therapists, or physiotherapists who performed spirometry at each site were blinded to each patient's study treatment assignment.
  • Finally, the correctness and validity of individual FEV1 curves and their resulting value had to be approved in a central and blinded reading by a pulmonary expert who was independent and not involved in patient care or treatment. The implementation of these measures should have ensured that the reported data of the primary outcome was as free as possible of bias induced by the open-label trial design.

Stratification prior to randomization was performed to limit imbalances between treatment arms with respect to key variables and potential confounders.

There were major recruitment issues in both the BOSTON-1 trial (SLT recipients) and the present BOSTON-2 trial, in part due to Coronavirus disease-2019 (COVID-19) and specifically in BOSTON-1 due to a marked decline over time in the use of SLT. Following FDA recommendation to obtain an adequately sized safety database for inhaled L-CsA and reach the originally planned sample size for BOSTON-1 and BOSTON-2 trials combined, it was planned to stop randomization into the two Phase III clinical trials upon achievement of a combined total of approximately 220 patients, of which approximately 160 to 170 patients were planned for enrollment in BOSTON-2. To assure balance between treatment arms with regard to key variables and potential confounders, stratification prior to randomization was performed. Within each of the 8 strata, using a permuted blocks randomization, patients were randomly assigned with equal probability (1:1) to receive either L-CsA (10 mg) via the PARI eFlow Nebulizer System twice daily (BID) plus SoC treatment or SoC alone, for a period of 48 weeks. Patients were monitored every 4 to 8 weeks over 48 weeks for efficacy parameters and for all safety evaluations. All patients were eligible to continue in an open-label extension trial of L-CsA, BOSTON-3 (Study BT-L-CsA-303-FU) following completion of either BOSTON-1 or BOSTON-2.

Up to 11 visits (Screening, V1 through V10) were planned during the clinical trial. After informed consent had been obtained, a Screening Visit was carried out to check general eligibility for participation. At the Baseline Visit (V1, Randomization Visit), inclusion and exclusion criteria were re-checked, and Baseline serial spirometry was performed. During the 48-week treatment period, visits were scheduled every 4 to 8 weeks (V2 to V9). Visit 9 (End of Treatment [EoT) was scheduled to occur 48 weeks after Visit 1. If a patient had an event that met the first criterion for progression of BOS, progression of BOS must have been confirmed by measurements that were taken with COMPACT spirometer at least 2 weeks apart. Visit 10 (EoS) was a safety follow-up visit performed 4 weeks after Visit 9/EoT only in patients not rolling over to the extension study (BOSTON-3). For patients who rolled over to BOSTON-3, the EoT Visit was the EoS Visit. Every effort was made to have all planned and unscheduled visits at the study site. However, if one of the visits from Visit 2 to Visit 8 and discontinuation visits could not be performed at the site due to COVID-19, remote visits (e.g., by telephone) were possible. Mandatory on-site visits were Screening Visit, Visit 1, and Visit 9.

03

Conditions studied

  • Bronchiolitis Obliterans
  • Chronic Rejection of Lung Transplant
  • Lung Transplant Rejection
  • Lung Transplant; Complications
  • Lung Transplant Failure and Rejection
  • Chronic Lung Allograft Dysfunction
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

Patients who met the following criteria as stated in the protocol were included in the study:

  1. Adult patients of > or = 18 years who received a DLT at least 12 months prior to Screening.
  2. Patients with BOS diagnosis defined as CLAD-BOS phenotype with:

    1. screening between 51% and 85% of personal best FEV1 value post-transplant OR
    2. screening FEV1 > 85% of personal best FEV1 associated with EITHER a > or = 200 mL decrease in FEV1 in the previous 12 months OR according to medical history showing BOS progression.
  3. Diagnosis of CLAD-BOS must have been made at least 12 months after lung transplantation and

    1. within 12 months prior to the Screening Visit OR
    2. more than 12 months from Screening and patient must have shown a decline in FEV1 >or = 200 ml in the previous 12 months before Screening, which was not due to acute infection or acute organ rejection.
  4. Patients in whom the diagnosis of BOS had been confirmed by the elimination of other possible causes of obstructive or restrictive lung disease CLAD - restrictive allograft syndrome (RAS) phenotype.
  5. Patients should have been on a drug maintenance regimen of agents including tacrolimus, a second agent such as but not limited to MMF or azathioprine, and a systemic such as prednisone as third agent. The regimen must have been stable within 4 weeks prior to randomization with respect to the therapeutic agents. In case a patient was also receiving concomitant azithromycin for prophylaxis or treatment of BOS, in addition to the previously described immunosuppressive regimen, azithromycin must have been on a stable regimen for at least 4 weeks prior to randomization.
  6. Patients capable of understanding the purposes and risks of the clinical trial, who had given written and agreed to comply with the clinical trial requirements/visit schedules, and who were capable of aerosol inhalation. Patients must have consented to retrieve prespecified data from the historic medical record (e.g., information related to the transplant surgery; spirometry data; medication use).
  7. Women of must have had a negative serum or urine pregnancy test within 7 days prior to randomization and must have agreed to use one of the methods of listed in Appendix II of the protocol in Appendix 16.1.1 through their EoS Visit.
  8. Patients had no concomitant diagnoses that were considered fatal within one year (12 months) of Screening.

Exclusion criteria

Exclusion Criteria:

  1. Patients with confirmed other causes for loss of lung function, such as acute infection, acute rejection, restrictive allograft syndrome (RAS) (CLAD - RAS phenotype, see Protocol Specific Definition ), etc.
  2. Cystic Fibrosis patients with multi-drug resistant infections not responding to available anti-microbial therapies.
  3. Patients with acute antibody-mediated rejection at Screening. In this context, clinically stable patients (as judged by the Investigator) with detectable levels of donor specific antibodies (DSA) at the Screening Visit are eligible for the study.
  4. Active acute bacterial, viral, or fungal infection not successfully resolved at least 4 weeks prior to the Screening Visit. Patients with chronic infection or colonization who are clinically stable as per judgement of the Investigator are eligible for the study.
  5. Mechanical ventilation (including CPAP) within 12 weeks prior to Randomization.
  6. Patients with uncontrolled hypertension.
  7. Patient has baseline resting oxygen saturation of \< 89% on room air or use of supplemental oxygen at rest.
  8. Evidence of functional airway stenosis (e.g., bronchomalacia/tracheomalacia, airway stents, or airways requiring balloon dilatations to maintain patency) with onset after the initial diagnosis of BOS and ongoing at Screening and/or Randomization Visit.
  9. Known to L-CsA or to cyclosporine A.
  10. Patients with chronic renal failure, defined as serum creatinine > 2.5 mg/dL at screening, or requiring chronic dialysis.
  11. Patients with liver disease and serum > 3-fold or transaminases > 2.5 upper limit of normal range.
  12. Patients with active within the previous 2 years, including post-transplant lymphoproliferative disorder, with the exception of treated, localized basal and squamous cell carcinomas.
  13. Pregnant women or women who are unwilling to use appropriate to avoid pregnancy through their End of Study Visit.
  14. Women who are currently breastfeeding.
  15. Receipt of an drug as part of a clinical trial within 4 weeks prior to the Screening Visit. This is defined as any treatment that is implemented under an Investigational New Drug (IND) or compassionate use.
  16. Patients who have received extracorporeal photophoresis (ECP) for treatment of BOS within 1 month prior to Randomization.
  17. Patients who are currently participating in an interventional clinical trial.
  18. Psychiatric disorders or altered mental status precluding understanding of the process and/or completion of the necessary procedures.
  19. Any co-existing medical condition that in the Investigator's judgment will substantially increase the risk associated with the patient's participation in the clinical trial.
Terms in these criteria, in plain language(11)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

FEV1

From a breathing test (spirometry): how much air you can blow out in the first second. Often given as a percentage of what is expected for your age, height and sex.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Single (Outcomes assessor)
Enrollment
169 participants (actual)

Study arms

  • Experimental
    L-CsA treatment plus SoC

    Liposomal Cyclosporine A (L-CsA) 10 mg twice daily for 48 weeks, plus Standard of Care Therapy

    Drug: Liposomal Cyclosporine A

  • Active comparator
    Standard of Care

    This is a maintenance regimen of immunosuppressive agents

    Drug: Standard of Care

Interventions

  • This formulation is developed for inhalation use and delivered via the PARI eFlow® Device, which is a new technology of nebulizing liquid drugs with a perforated vibrating membrane resulting in an aerosol with a low ballistic momentum and a high percentage of droplets in a respirable size range of 3-5 μm. The L-CsA was administered as 10 mg/2.4 mL inhalation via the PARI eFlow device BID (morning/evening, approximately 12 hours apart) for 48 weeks. Nebulization time per inhalation dose was approximately 6 to 17 minutes. Patients received training on the use of the device and the first dose of L-CsA was self-administered by each patient under the supervision of trained personnel. In addition, during all subsequent scheduled visits the L-CsA inhalation was self-administered by the patient and under the supervision of trained study personnel.

    Also known as: L-CsA

  • DrugStandard of Care

    Standard of Care Therapy (SoC). The SoC included maintenance immunosuppressive medication including tacrolimus, a second agent such as but not limited to MMF or azathioprine, and a systemic corticosteroid such as prednisone as third agent; but also a prophylaxis against common opportunistic infections, and all other necessary medications and therapies for the optimal care of the patient. This also included vaccination against COVID-19 All changes in concurrent treatment or medication were administered according to site's SoC. The regimen must be stable within 4 weeks prior to randomization with respect to the therapeutic agents. Patients receiving azithromycin for prophylaxis or treatment of BOS, should be on a stable regimen for a least 4-weeks prior to randomization and continued to receive azithromycin during the trial as deemed appropriate by the investigator.

    Also known as: SoC

06

What researchers measure

Primary outcomes

  1. Mean Change in FEV1 (Liters) From Baseline to Week 48

    FEV1 is the Forced Expiratory Volume in One Second. The FEV1 data collected from the on-site COMPACTTM spirometer were to be considered primary, while data collected with the In2itiveTM home spirometer were to be used for supportive analyses.

    Time frame: Week 48

Secondary outcomes

  1. Mean Change in FEV1/ Forced Vital Capacity (FVC) From Baseline to Week 48

    Forced Expiratory Volume in One Second on Forced Vital Capacity. It was analysed in the FAS using a LMM for repeated measurements, with baseline FEV1/FVC among covariates. In case of death or re- transplantation events, FEV1/FVC was imputed as zero at each nominal day post event. FEV1/FVC is a calculated ratio used to diagnose obstructive and restrictive lung disease. It represents the proportion of a patient's vital capacity that he/she is able to expire in the first second of forced expiration to the full forced vital capacity.

    Time frame: Week 48

  2. Time to Progression of Bronchiolitis Obliterans Syndrome (BOS)

    Time to progression of BOS, defined as the earliest of the following: * Absolute decrease from Baseline in FEV1 ≥10% or ≥ 200 mL (0.2 L) and absolute decrease in FEV1/FVC of \> 5% OR * Worsening of BOS grade, OR * Re-transplantation, OR * Death from respiratory failure. More than one type of event might correspond to the event of BOS progression (even those occurring on the same date). In case progression of BOS was defined by more than one criterion on different dates, the earliest event date was considered, i.e., the date closer to randomization was used as the progression date.

    Time frame: From date of randomization until the date of first documented progression of BOS, or date of retransplantation, or date of death from respiratory failure, whichever came first, assessed up to 48 weeks.

Other outcomes

  1. Acute Tolerability of L-CsA: FEV1 Change From Pre-dose to 1 Hour and 4 Hours Post-dose

    Acute tolerability of IMP (L-CsA) during initial dosing was determined by measuring spirometry 1 hour and 4 hours after treatment. The FEV1 was measured prior to dosing with L-CsA. A decline of ≥20% associated with symptoms could have warranted IMP discontinuation. Parameters reflecting acute tolerability of IMP were: spirometry, cough, or dyspnea.

    Time frame: Pre-dose and 1- and 4-hours post-dose on Visit 1

  2. Count of Participants With at Least One Adverse Event (AE)

    An untoward medical occurrence after exposure to a medicine, which is not necessarily caused by that medicine.

    Time frame: Baseline through study completion (52 weeks)

07

Results

Posted Jul 24, 2025

Participant flow

The COVID-19 pandemic impacted the conduct of the study. Based on the evolution of the outbreak and in accordance with country- and site-specific determinations, recruitment was put on hold starting on 20 March 2020. Recruitment was subsequently resumed in Quarter 3 2020. COVID- 19 might have affected the results for different reasons including changes in infection rate and type, quarantining, social distancing, and other considerations linked to different ways each site managed the pandemic.

Participant flow — Overall Study
MilestoneL-CsA Treatment Plus SoCStandard of Care
Started8485
Full analysis set8485
Safety analysis set8485
Per protocol set4670
Completed6979
Not completed156
Withdrew: Adverse event54
Withdrew: Withdrawal by subject72
Withdrew: Screen fail after randomization10
Withdrew: Pi decision due to patient condition10
Withdrew: Patient unresponsiveness10

Outcome measures

PrimaryMean Change in FEV1 (Liters) From Baseline to Week 48

FEV1 is the Forced Expiratory Volume in One Second. The FEV1 data collected from the on-site COMPACTTM spirometer were to be considered primary, while data collected with the In2itiveTM home spirometer were to be used for supportive analyses.

Time frame:
Week 48
Reported as:
Least squares mean · Liters
Mean Change in FEV1 (Liters) From Baseline to Week 48
LitersL-CsA Treatment Plus SoC - FASStandard of Care - FAS
Mean Change in FEV1 (Liters) From Baseline to Week 48-0.096 ± 0.1120-0.067 ± 0.1147
Statistical analysis
  • L-CsA Treatment Plus SoC - FAS vs Standard of Care - FAS · Mixed Models Analysis · p = 0.6639 (This is a 1-side p value.) · Least square mean difference: -0.028 · 95% CI -0.160 to 0.104
SecondaryMean Change in FEV1/ Forced Vital Capacity (FVC) From Baseline to Week 48

Forced Expiratory Volume in One Second on Forced Vital Capacity. It was analysed in the FAS using a LMM for repeated measurements, with baseline FEV1/FVC among covariates. In case of death or re- transplantation events, FEV1/FVC was imputed as zero at each nominal day post event. FEV1/FVC is a calculated ratio used to diagnose obstructive and restrictive lung disease. It represents the proportion of a patient's vital capacity that he/she is able to expire in the first second of forced expiration to the full forced vital capacity.

Time frame:
Week 48
Reported as:
Least squares mean · ratio
Mean Change in FEV1/ Forced Vital Capacity (FVC) From Baseline to Week 48
ratioL-CsA Treatment Plus SoC - FASStandard of Care - FAS
Mean Change in FEV1/ Forced Vital Capacity (FVC) From Baseline to Week 48-0.100 ± 0.0722-0.083 ± 0.0702
Statistical analysis
  • L-CsA Treatment Plus SoC - FAS vs Standard of Care - FAS · Mixed Models Analysis · p = 0.7792 · Least square mean difference: -0.016 · 95% CI -0.057 to 0.025
SecondaryTime to Progression of Bronchiolitis Obliterans Syndrome (BOS)

Time to progression of BOS, defined as the earliest of the following: * Absolute decrease from Baseline in FEV1 ≥10% or ≥ 200 mL (0.2 L) and absolute decrease in FEV1/FVC of \> 5% OR * Worsening of BOS grade, OR * Re-transplantation, OR * Death from respiratory failure. More than one type of event might correspond to the event of BOS progression (even those occurring on the same date). In case progression of BOS was defined by more than one criterion on different dates, the earliest event date was considered, i.e., the date closer to randomization was used as the progression date.

Time frame:
From date of randomization until the date of first documented progression of BOS, or date of retransplantation, or date of death from respiratory failure, whichever came first, assessed up to 48 weeks.
Reported as:
Median · weeks
Time to Progression of Bronchiolitis Obliterans Syndrome (BOS)
weeksL-CsA Treatment Plus SoC - FASStandard of Care - FAS
Time to Progression of Bronchiolitis Obliterans Syndrome (BOS)NA (NA to NA)NA (NA to NA)
Statistical analysis
  • L-CsA Treatment Plus SoC - FAS vs Standard of Care - FAS · Regression, Cox · p = =0.3110 (1-sided p value. The adjusted hazard ratio was calculated using Cox proportional hazards model, with covariates of treatment, age (\< 55 vs \> or= 55 years) with Efron's method of tie handling.) · Adjusted hazard ratio: 1.19 · 95% CI 0.589 to 2.420
Other pre-specifiedAcute Tolerability of L-CsA: FEV1 Change From Pre-dose to 1 Hour and 4 Hours Post-dose

Acute tolerability of IMP (L-CsA) during initial dosing was determined by measuring spirometry 1 hour and 4 hours after treatment. The FEV1 was measured prior to dosing with L-CsA. A decline of ≥20% associated with symptoms could have warranted IMP discontinuation. Parameters reflecting acute tolerability of IMP were: spirometry, cough, or dyspnea.

Time frame:
Pre-dose and 1- and 4-hours post-dose on Visit 1
Reported as:
Mean · Liters
Acute Tolerability of L-CsA: FEV1 Change From Pre-dose to 1 Hour and 4 Hours Post-dose
LitersL-CsA Treatment Plus SoC - SAF
1h post-dose-0.019 ± 0.0855
4h post-dose-0.005 ± 0.0914
Other pre-specifiedCount of Participants With at Least One Adverse Event (AE)

An untoward medical occurrence after exposure to a medicine, which is not necessarily caused by that medicine.

Time frame:
Baseline through study completion (52 weeks)
Reported as:
Count of participants · Participants
Count of Participants With at Least One Adverse Event (AE)
ParticipantsL-CsA Treatment Plus SoC - SAFStandard of Care SAF
with any TEAE7377
with any TEAE Leading to discontinuation of study treatment120
with any TEAE Leading to study discontinuation53
with any TEAE Leading to death24
with any TEAE mild6668
with any TEAE moderate5056
with any TEAE severe2118
with any study treatment-related TEAE390
with any serious TEAE4644

Adverse events

Collected over From baseline throughout the study, till week 52.. Non-serious events are listed at a 0% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
L-CsA Treatment Plus SoC - SAF2/84 (2.4%)46/84 (54.8%)73/84 (86.9%)
Standard of Care - SAF4/85 (4.7%)44/85 (51.8%)77/85 (90.6%)
Most frequent serious events
Showing 10 of 20
Most frequent serious events
EventL-CsA Treatment Plus SoC - SAFStandard of Care - SAF
COVID-19Infections and infestations23/8421/85
COVID-19 pneumoniaInfections and infestations5/841/85
Acute kidney injuryRenal and urinary disorders5/842/85
BronchitisInfections and infestations3/841/85
GastroenteritisInfections and infestations3/840/85
PneumoniaInfections and infestations3/843/85
Respiratory failureRespiratory, thoracic and mediastinal disorders2/843/85
Acute respiratory failureRespiratory, thoracic and mediastinal disorders2/841/85
DyspnoeaRespiratory, thoracic and mediastinal disorders2/841/85
HypoxiaRespiratory, thoracic and mediastinal disorders2/841/85
Most frequent other events
Showing 10 of 338
Most frequent other events
EventL-CsA Treatment Plus SoC - SAFStandard of Care - SAF
COVID-19Infections and infestations23/8421/85
CoughRespiratory, thoracic and mediastinal disorders19/847/85
Disease progressionGeneral disorders16/8415/85
DyspnoeaRespiratory, thoracic and mediastinal disorders9/845/85
Throat irritationRespiratory, thoracic and mediastinal disorders9/840/85
BronchitisInfections and infestations8/845/85
DiarrhoeaGastrointestinal disorders8/846/85
HeadacheNervous system disorders8/840/85
NasopharyngitisInfections and infestations6/848/85
Oedema peripheralGeneral disorders7/847/85

Baseline characteristics

Full Analysis Set (FAS): The FAS was defined as all randomized patients. Patients were analyzed according to the treatment group to which they were randomized. All primary, secondary and exploratory endpoints were performed using the FAS, unless otherwise specified.

Age, Categorical
Age, Categorical(Participants)L-CsA Treatment Plus SoC - SAFStandard of Care - SAFTotal
<=18 years000
Between 18 and 65 years5864122
>=65 years262147
Age, Continuous
Age, Continuous(years)L-CsA Treatment Plus SoC - SAFStandard of Care - SAFTotal
Mean56.5 ± 12.6956.2 ± 10.8256.3 ± 11.75
Sex: Female, Male
Sex: Female, Male(Participants)L-CsA Treatment Plus SoC - SAFStandard of Care - SAFTotal
Female344276
Male504393
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)L-CsA Treatment Plus SoC - SAFStandard of Care - SAFTotal
Hispanic or Latino6410
Not Hispanic or Latino7071141
Unknown or Not Reported81018
Race (NIH/OMB)
Race (NIH/OMB)(Participants)L-CsA Treatment Plus SoC - SAFStandard of Care - SAFTotal
American Indian or Alaska Native000
Asian112
Native Hawaiian or Other Pacific Islander000
Black or African American257
White7570145
More than one race415
Unknown or Not Reported2810
Region of Enrollment
Region of Enrollment(participants)L-CsA Treatment Plus SoC - SAFStandard of Care - SAFTotal
Austria235
Belgium426
United States303161
Denmark134
United Kingdom336
Israel415
France4812
Germany151934
Spain211536
08

Study locations

40 sites
  • Banner Health
    Phoenix, Arizona 85013, United States
  • UCLA Medical Center
    Los Angeles, California 90095, United States
  • Stanford University Hospital
    Palo Alto, California 94305, United States
  • UC San Francisco
    San Francisco, California 94143, United States
  • University of Florida Medical Center
    Gainesville, Florida 32608, United States
  • Mayo Clinic Jacksonville
    Jacksonville, Florida 32224, United States
  • University of South Florida
    Tampa, Florida 33606, United States
  • Indiana University
    Indianapolis, Indiana 46202, United States
  • University of Kentucky Albert B. Chandler Hospital
    Lexington, Kentucky 40508, United States
  • University of Maryland
    Baltimore, Maryland 21201, United States
  • Johns Hopkins University Hospital
    Baltimore, Maryland 21287, United States
  • Washington University
    St Louis, Missouri 63110, United States
  • Columbia University Medical Center
    New York, New York 10032, United States
  • Duke University Medical Center
    Durham, North Carolina 27110, United States
  • Cleveland Clinic
    Cleveland, Ohio 44195, United States
  • Ohio State University Medical Center
    Columbus, Ohio 43210, United States
  • Temple University Hospital
    Philadelphia, Pennsylvania 19140, United States
  • University of Pittsburgh Medical Center
    Pittsburgh, Pennsylvania 15232, United States
  • Baylor University Medical Center
    Dallas, Texas 75246, United States
  • Baylor College of Medicine
    Houston, Texas 77030, United States
  • Houston Methodist Hospital
    Houston, Texas 77030, United States
  • Medical University of Vienna
    Vienna, Austria
  • CHU Erasme
    Brussels, Belgium
  • Universitair Ziekenhuis Leuven
    Leuven, 3000, Belgium
  • Copenhagen University Hospital
    Copenhagen, Denmark
  • Marie-Lannelongue
    Le Plessis-Robinson, 92350, France
  • CHU Hopital Nord
    Marseille, France
  • Hôpitaux Universitaires de Strasbourg
    Strasbourg, France
  • Hannover Medical School
    Hanover, Germany
  • LMU Klinikum Großhadern
    Munich, Germany
  • Rabin Medical Center
    Petah Tikva, Israel
  • Complexo Hospitalario de A Coruna
    A Coruña, Spain
  • Hospital Universitari Vall d'Hebron
    Barcelona, Spain
  • Hospital Universitario Reina Sofía
    Córdoba, 14004, Spain
  • Hospital Universitario 12 de Octubre
    Madrid, 28041, Spain
  • Hospital Puerta de Hierro
    Madrid, Spain
  • Hospital Marques de Valdecilla
    Santander, Spain
  • University Hospital LA Fe
    Valencia, Spain
  • Royal Papworth Hospital
    Cambridge, United Kingdom
  • University of Manchester
    Manchester, United Kingdom
09

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Mar 2019 to primary completion in Mar 2024, 59 months.

Results were first posted in Jul 2025, 1 year 4 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Aug 30, 2018
First posted
Sep 4, 2018
StartActual
Mar 26, 2019
Primary completionActual
Mar 12, 2024
CompletionActual
Mar 12, 2024
Results first posted
Jul 24, 2025
Last update
Feb 10, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Feb 10, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT03656926
Lead sponsor
Zambon SpA
Responsible party
Sponsor
First posted
Sep 4, 2018
Start date
Mar 26, 2019
Primary completion
Mar 12, 2024
Completion
Mar 12, 2024
Results posted
Jul 24, 2025
Last update
Feb 10, 2026

Study contacts

Paola Castellani, MD
study director · Zambon SpA, Chief Medical Officer and R&D

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Feb 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Cyclosporine

Start the discussion